ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GWP GW Pharm.

735.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
GW Pharm. LSE:GWP London Ordinary Share GB0030544687 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 735.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

GW Pharmaceuticals PLC Date and Time Change for Q4 and FY 2015 Results (3899H)

30/11/2015 1:00pm

UK Regulatory


Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Gw Pharmaceuticals Charts.

TIDMGWP

RNS Number : 3899H

GW Pharmaceuticals PLC

30 November 2015

GW Pharmaceuticals Announces Date and Time Change for Q4 and Year-End 2015 Financial Results and Conference Call

-Change to after market on 7 December to facilitate inclusion of additional Epidiolex data-

London, UK, 30 Nov 2015: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces that it has changed the date and time for the release of its fourth quarter and year-end results and associated conference call to facilitate inclusion of newly available data from the physician-led Epidiolex(R) expanded access program.

The new date and time for GW's fourth quarter and year-end financial results for the period ending 30 September will be Monday 7 December, 2015 at 4:00 p.m. EST (9:00 p.m. GMT).

GW will also host a conference call the same day at 4:30 p.m. EST (9:30 p.m. GMT). Conference call information will be provided in the financial results press release issued after the U.S. market close that day. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R) , which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) , which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc              (Today) +44 20 3727 1000 
 Stephen Schultz, VP Investor        917 280 2424 / 401 500 
  Relations (U.S.)                    6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway           + 44 20 3727 1000 
 
   Peel Hunt LLP (UK NOMAD) 
 James Steel                         +44 20 7418 8900 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLBLFXEFFLFBK

(END) Dow Jones Newswires

November 30, 2015 08:00 ET (13:00 GMT)

1 Year Gw Pharmaceuticals Chart

1 Year Gw Pharmaceuticals Chart

1 Month Gw Pharmaceuticals Chart

1 Month Gw Pharmaceuticals Chart